Development and validation of LC-MS/MS method for the quantitation of lenalidomide in human plasma using Box-Behnken experimental design

Analyst

Volumn 138, Issue 5, 2013, Pages 1581-1588

  Hasnain, M Saquib ^a   Rao, Shireen ^b   Singh, Manoj Kr ^b   Vig, Nitin ^b   Gupta, Amit ^b   Ansari, Abdulla ^b   Sen, Pradeep ^b   Joshi, Pankaj ^b   Ansari, Shaukat Ali ^b  

^a SEEMANTA INSTITUTE OF PHARMACEUTICAL SCIENCES   (India)

^b Fortis Clinical Research Limited   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84873673742     PISSN: 00032654     EISSN: 13645528     Source Type: Journal    
DOI: 10.1039/c2an36701g     Document Type: Article

References (16)

1. J. B. Bartlett K. Dredge A. G. Dalgleish The evolution of thalidomide and its IMiD derivatives as anticancer agents Nat. Rev. Cancer 2004 4 314 322
2. P. G. Richardson S. Jagannath R. Schlossman S. Zeldenrust S. V. Rajkumar M. Alsina K. R. Desikan C. S. Mitsiades K. Kelly D. Doss M. McKenney S. Gorelik D. A. Warren A. Freeman R. Rich R. Knight M. Olesnyckyj J. Patin J. Zeldis W. Dalton K. C. Anderson Blood 2003 102 825
3. K. C. Anderson Lenalidomide and thalidomide: mechanisms of action-similarities and differences Semin. Hematol. 2005 42 S3 S8
4. K. Dredge R. Horsfall S. P. Robinson L. H. Zhang L. Lu Y. Tang M. A. Shirley G. Muller P. Schafer D. Stirling A. G. Dalgliesh J. B. Bartlet Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro Microvasc. Res. 2005 69 56 63
5. A. A. Giagounidis U. Germing C. Aul Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies Clin. Cancer Res. 2006 12 5 10
6. A. Naing L. Sokol A. F. List Developmental therapeutics for myelodysplastic syndromes J. Natl. Compr. Cancer Network 2006 1 78 82
7. A. A. Giagounidis U. Germing C. Strupp B. Hildebrandt M. Heinsch C. Aul Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup Ann. Hematol. 2005 84 569 571
8. A. List S. Kurtin D. J. Roe A. Buresh D. Mahadevan D. Fuchs L. Rimsza R. Heaton R. Knight J. B. Zeldis Efficacy of lenalidomide in myelodysplastic syndromes N. Engl. J. Med. 2005 352 549 557
9. K. McClellan B. Jarvis Desloratadine. Drugs. 2001 61 789 796
10. L. Liu M. Qi P. Wang H. J. Li High-performance liquid chromatographic method for the bioequivalence evaluation of desloratadine fumarate tablets in dogs J. Pharm. Biomed. Anal. 2004 34 1013 1019
11. F. C. Sutherland A. D. De Jager D. Badenhorst T. Scanes H. K. Hundt K. J. Swart A. F. Hundt Sensitive liquid chromatography-tandem mass spectrometry method for the determination of loratadine and its major active metabolite descarboethoxyloratadine in human plasma J. Chromatogr., A 2001 914 37 43
12. T. M. Tohniya K. Hwang E. R. Lepper H. A. Fine W. L. Dahut J. Venitz A. Sparreboom W. D. Figg Determination of CC-5013, an analogue of thalidomide, in human plasma by liquid chromatography-mass spectrometry J. Chromatogr., B: Anal. Technol. Biomed. Life Sci. 2004 811 135 141
13. M. E. Bosch A. J. R. Sanchez F. S. Rojas C. B. Ojeda Recent advances in analytical determination of thalidomide and its metabolites J. Pharm. Biomed. Anal. 2008 46 9 17
14. L. A. Svensson J. Dönnecke K. E. Karlsson A. Karlsson J. Vessman Vancomycin-based chiral stationary phases for micro-column liquid chromatography Chirality 1999 11 121 128
15. S. K. Teo R. S. Chandula J. L. Harden D. I. Stirling S. D. Thomas Sensitive and rapid method for the determination of thalidomide in human plasma and semen using solid-phase extraction and liquid chromatography-tandem mass spectrometry J. Chromatogr., B: Anal. Technol. Biomed. Life Sci. 2002 767 145 151
16. S. Beg K. Kohli S. Swain M. S. Hasnain Development and validation of RP-HPLC method for quantitation of amoxicillin trihydrate in bulk and pharmaceutical formulation using Box-Behnken experimental design J. Liq. Chromatogr. Relat. Technol. 2012 35 393 406